Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

An alternative test for acetylator phenotyping with caffeine.

B K Tang1, D Kadar, W Kalow

  • 1Department of Pharmacology, University of Toronto, Ontario, Canada.

Clinical Pharmacology and Therapeutics
|November 1, 1987
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pharmacogenetics and pharmacogenomics: origin, status, and the hope for personalized medicine.

The pharmacogenomics journal·2006
Same author

A simple test for acetylator phenotype using caffeine. 1984.

British journal of clinical pharmacology·2004
Same author

Both populations and individuals are evolutionary targets: pharmacogenomic and cultural indicators.

The pharmacogenomics journal·2002
Same author

Multigenic traits and risk assessment in pharmacology: a population approach.

The pharmacogenomics journal·2002
Same author

Treatment-resistance to clozapine in association with ultrarapid CYP1A2 activity and the C-->A polymorphism in intron 1 of the CYP1A2 gene: effect of grapefruit juice and low-dose fluvoxamine.

Journal of clinical psychopharmacology·2002
Same author

Detailed characterization of experimentally derived human hepatic CYP1A1 activity and expression using differential inhibition of ethoxyresorufin O-deethylation by fluvoxamine.

European journal of clinical pharmacology·2001

This study introduces a reproducible caffeine metabolite ratio for determining genetically controlled acetylator status. The method accurately distinguishes between slow and fast acetylators, aiding in phenotype assessment.

Area of Science:

  • Pharmacogenetics
  • Biochemical analysis

Background:

  • Acetylator status, a genetically controlled trait, influences drug metabolism.
  • Caffeine metabolism yields a labile acetylated uracil (5-acetylamino-6-formylamino-3-methyluracil) that can be converted to a stable form (5-acetylamino-6-amino-3-methyluracil).

Purpose of the Study:

  • To assess the intraindividual variability of caffeine metabolite ratios for acetylator phenotype determination.
  • To validate a new ratio for distinguishing slow and fast acetylators in a population.

Main Methods:

  • Longitudinal study of three subjects assessing metabolite ratios under varying caffeine intake and urine collection conditions.
  • Exclusion chromatography used for quantifying the stable caffeine metabolite.
  • Comparison of the developed ratio with the plasma index for sulfamethazine acetylation.

Related Experiment Videos

Main Results:

  • A reproducible ratio of 5-acetylamino-6-amino-3-methyluracil to paraxanthine 7-demethylation products was identified, especially with overnight urine after daytime coffee consumption.
  • This ratio demonstrated high reproducibility and complete concordance with the sulfamethazine acetylation plasma index.
  • The ratio effectively separated slow and fast acetylators in a population study, with potential to differentiate homozygous and heterozygous fast acetylators.

Conclusions:

  • A reliable and reproducible method for determining acetylator phenotype using caffeine metabolites has been established.
  • This method offers a practical approach for population studies and clinical applications in pharmacogenetics.